84324-68-5

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-N-(pyridin-3-ylmethyl)aniline is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new medications. Its unique structure allows it to be a key component in the creation of drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-bromo-N-(pyridin-3-ylmethyl)aniline is utilized as an intermediate in the production of agrochemicals, potentially enhancing crop protection and management through the development of novel compounds with targeted pest control capabilities.
Used in Medicinal Chemistry Research:
4-bromo-N-(pyridin-3-ylmethyl)aniline serves as a valuable building block in medicinal chemistry, where it is employed in the design and synthesis of new drug candidates. Its structural features make it a promising component in the advancement of therapeutic agents with improved efficacy and selectivity.
Used in Controlled Laboratory Settings:
Due to its potential hazardous properties, 4-bromo-N-(pyridin-3-ylmethyl)aniline is used in controlled laboratory settings to ensure safety during its manipulation and application in chemical reactions and drug development processes. This controlled use helps mitigate risks associated with its handling and promotes responsible chemical research and development.

InChI:InChI=1/C12H11BrN2/c13-11-3-5-12(6-4-11)15-9-10-2-1-7-14-8-10/h1-8,15H,9H2

Upstream product

• 500-22-1 3-pyridinecarboxaldehyde 
• 106-40-1 4-bromo-aniline 
• 586-78-7 para-nitrophenyl bromide 

Downstream Products

• 353235-63-9 N-[4-(2-methoxyphenoxy)phenyl]pyridin-3-ylmethylamine 

Relevant academic research and scientific papers

MOF-derived cobalt nanoparticles catalyze a general synthesis of amines

The development of base metal catalysts for the synthesis of pharmaceutically relevant compounds remains an important goal of chemical research. Here, we report that cobalt nanoparticles encapsulated by a graphitic shell are broadly effective reductive amination catalysts. Their convenient and practical preparation entailed template assembly of cobaltdiamine- dicarboxylic acid metal organic frameworks on carbon and subsequent pyrolysis under inert atmosphere.The resulting stable and reusable catalysts were active for synthesis of primary, secondary, tertiary, and N-methylamines (more than 140 examples).The reaction couples easily accessible carbonyl compounds (aldehydes and ketones) with ammonia, amines, or nitro compounds, and molecular hydrogen under industrially viable and scalable conditions, offering cost-effective access to numerous amines, amino acid derivatives, and more complex drug targets.

RESORCINOL N-ARYL AMIDE COMPOUNDS, FOR USE AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS

A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: Y is –CONR1- or optionally substituted arylene or optionally substituted heteroarylene; R1 is H, Cl, F, CH3 or CF3; 10 each R4 is independently H, CH3 or F; R5 is H or CH3; and each R2 and R6 is independently (Alk)n-Rn-(Alk)n-Rn-(Alk)n-X; The compounds of the invention are useful as resorcinol N-aryl amide (NAA) compounds, which are suitable for use as PDK inhibitors, for example for 15 inhibition of cancer cell proliferation.

Potentiators of glutamate receptors

The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.

Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: Synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3- ylmethylamine

This report describes recently discovered novel allosteric modulators of metabotropic glutamate2 (mGlu2) receptors. These pyridylmethylsulfonamides (e.g., 3) potentiate glutamate, shifting agonist potency by 2-fold. This effect was specific for mGlu2 (vs